29th week of 2015 patent applcation highlights part 7 |
Patent application number | Title | Published |
20150196597 | Acellular Pro-Tolerogenic Compositions for Treatment/Prevention of Graft Rejection - This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses for preventing or limiting graft rejection and GVHD of such compositions are also provided. | 2015-07-16 |
20150196598 | HUMAN CD8+ REGULATORY T CELLS INHIBIT GVHD AND PRESERVE GENERAL IMMUNITY IN HUMANIZED MICE - Graft-versus-host disease (GVHD) is a lethal complication of allograft transplantation. The current strategy of using immunosuppressive agents to control GVHD may cause general immune suppression and limit the effectiveness of allograft transplantation. Adoptive transfer of regulatory T cells (Treg) can prevent GVHD in rodents, indicating the therapeutic potential of Treg for GVHD in humans. However, the clinical application of Treg-based therapy is hampered by the low frequency of human Treg and the lack of a reliable model to test their therapeutic effects in vivo. Human alloantigen-specific Treg are generated from antigenically-naïve precursors in a large scale ex vivo using allogeneic activated B cells as stimulators. Here, a human allogeneic GVHD model is established in humanized mice to mimic GVHD after allograft transplantation in humans. The ex vivo-induced CD8 | 2015-07-16 |
20150196599 | Cell-Based Anti-Cancer Compositions With Reduced Toxicity And Methods Of Making And Using The Same - Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules. | 2015-07-16 |
20150196600 | PLURIPOTENT STEM CELL THAT INDUCES REPAIR AND REGENERATION AFTER MYOCARDIAL INFARCTION - An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders. | 2015-07-16 |
20150196601 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS - Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit. | 2015-07-16 |
20150196602 | STEM CELL THERAPY FOR CROHN'S DISEASE AND ULCERATIVE COLITIS - A therapeutic process for treating an inflammatory bowel disease (IBD) using mesenchymal stem cells includes the steps of isolating a plurality of human mesenchymal stem cells from a human patient, introducing the plurality of human mesenchymal stem cells into the human patient, reducing human pro-inflammatory cytokines, wherein the human pro-inflammatory cytokines include IL-12 and IL-18, and increasing human anti-inflammatory cytokines, wherein the human anti-inflammatory cytokines include IL-10 and TGF-beta. The human mesenchymal stem cells are isolated from an umbilical cord blood or from a human adipose tissue. The plurality of human mesenchymal stem cells is introduced into the human patient through a intravenous administration or through an enema. The plurality of human mesenchymal stem cells is reconstituted into growth factor rich plasma prior to being introduced into the human patient. | 2015-07-16 |
20150196603 | Novel Cell Compositions and Methods - The invention is directed to novel cell compositions termed AMP-N cells. In particular, the invention is directed to novel AMP-N cell compositions and novel compositions derived from the AMP-N cells including, but not limited to, novel cell-derived conditioned medium, termed ACCS-N. The invention is further directed to novel methods for making the novel AMP-N cell and ACCS-N compositions as well as uses thereof. | 2015-07-16 |
20150196605 | Compositions and Methods for Preventing Cardiac Arrhythmia - Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject. | 2015-07-16 |
20150196606 | ACTIVATOR OF GENE EXPRESSION OF MOLECULAR CHAPERONE GENE COMPRISING EGGSHELL MEMBRANE COMPONENT AND COMPOSITION THEREOF - To provide an activator of gene expression of molecular chaperone gene and applications thereof. | 2015-07-16 |
20150196607 | TREATING PANCREATIC CARCINOMA WITH A WHOLE, LEECH SALIVA EXTRACT - Methods are also provided for isolating and using a whole-saliva leech extract in the treatment of pancreatic carcinoma. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5° C. to about 40° C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about −20° C., the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant. | 2015-07-16 |
20150196608 | LACTOBACILLUS REUTERI GMNL-263 COMPOSITION FOR CONTROLLING BODY WEIGHT AND ITS USE THEREOF - Present invention features a method for controlling body weight, comprising | 2015-07-16 |
20150196609 | IBS Treatment - The invention relates to treatment of Irritable Bowel Syndrome using probiotic preparations containing viable, metabolically active probiotic bacteria. | 2015-07-16 |
20150196610 | Ultrasound-assisted high throughput continuous extraction for complete fragmentation of cocoa beans into valuable fractions and their formulations thereof - A process for the complete fractionation of cocoa beans with ‘zero waste’ into various value-added ingredients, a composition comprising cocoa polyphones/procyanidins and soluble dietary fiber, and a water dispersible and sustained release formulation of cocoa polyphones with cocoa soluble dietary fiber capable of forming a colloidal dispersion of bioactive cocoa polyphones in gastric fluid. | 2015-07-16 |
20150196611 | Pharmaceutical Composition and Methods for Modulating Immune System, Preventing, Pretreating and/or Treating Cancers - This invention provides a pharmaceutical composition for modulating immune system comprising at least one polysaccharide extracted from | 2015-07-16 |
20150196612 | Anti-enterovirus 71 steroidal saponins and their preparation - The present invention discloses a novel composition with anti-viral effects comprises extracts from | 2015-07-16 |
20150196613 | SAFFRON TREATMENT METHOD FOR MAMMALIAN MALADIES - A variety of medicinal compounds comprising | 2015-07-16 |
20150196614 | COMPOUNDS EXTRACTED FROM PALM OIL MILL EFFLUENT FOR THE TREATMENT OF CANCER, COMPOSITIONS THEREOF AND METHODS THEREWITH - The present invention describes a composition and methods for prevention and treatment of cancer comprising compounds extracted from Palm oil mill effluent. Also, the invention describes effective therapeutic dosages of the compounds and their combinations. The present invention can be prepared independently or as a combination product. | 2015-07-16 |
20150196615 | Methods for Treating HCV - The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). | 2015-07-16 |
20150196616 | ANGIOPOIETIN-LIKE 4 AND A METHOD OF ITS USE IN WOUND HEALING - A method and a pharmaceutical composition for increasing wound healing in an individual in need thereof, the method comprising administering an angiopoietin like 4 (ANGPTL4) polypeptide or a therapeutically active fragment thereof. | 2015-07-16 |
20150196617 | Peptide Analogs for Treating Diseases and Disorders - Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. Treatment is effected with a combination therapy of metformin and a peptide with a sequence selected from SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24 administered to a patient. | 2015-07-16 |
20150196618 | METHODS FOR DIAGNOSING, PROGNOSING AND TREATING MUSCULAR DYSTROPHY - Disclosed herein are methods for diagnosing, prognosing and treating muscular dystrophy. Also disclosed are methods of determining the effectiveness of an agent for the treatment of muscular dystrophy. Provided are methods of enhancing muscle regeneration, repair, or maintenance in a subject by administering galectin, such as Galectin-1 and/or Galectin-3 to a subject in need thereof. Also disclosed are methods of increasing or maintaining muscle strength and/or bone density in a subject by administering an effective amount of a Galectin-1 composition, Galectin-3 composition or a combination thereof to the subject in need thereof. Methods of preventing, inhibiting and/or reducing muscle loss and/or bone loss in a subject by administering an effective amount of a Galectin-1 composition, Galectin-3 composition or a combination thereof to the subject in need thereof are disclosed. | 2015-07-16 |
20150196619 | EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE RESPIRATORY TRACT - The present invention relates to methods of treating and preventing the inflammatory effects of viral infection of the upper and lower respiratory tracts, including infection by SARS coronovirus (SARS), pandemic Influenza A H5N1 (avian influenza) and pandemic influenza A H1N1 (swine 'flu). | 2015-07-16 |
20150196620 | SYSTEM AND METHOD FOR MULTIPHASIC RELEASE OF GROWTH FACTORS - A system for multiphasic delivery of at least one growth factor at a treatment site comprises a delivery vehicle for releasing at least one growth factor in an initial release profile and a carrier for releasing at least one growth factor in a sustained release profile. The initial release profile releases at least one growth factor over a period of hours to days, wherein the growth factor is released in a large amount initially, with the remainder being released in progressively lower amounts. The sustained release profile releases at least one growth factor over a period of days to weeks, wherein the growth factor is released at a generally constant amount over such period. The system of the invention is particularly suited for applications on bioimplants. The invention also comprises methods and kits for multiphasic delivery of at least one growth factor. The invention also comprises calcium sulphate as a carrier for releasing at least one growth factor in both single and multiphasic systems for delivering at least one growth factor at a treatment site. | 2015-07-16 |
20150196621 | COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF NEUROINJURY AND METHODS OF USE THEREOF - A method for preventing or ameliorating secondary neuronal injury and inflammation following traumatic brain injury (TBI) is disclosed. The method comprises the step of administering into a subject in need of such treatment an effective amount of a pharmaceutical composition containing a neuregulin (NRG), a variant of NRG, or an expression vector encoding a NRG or a variant of NRG. | 2015-07-16 |
20150196622 | MATERIALS AND METHODS FOR MODULATING GLUCOSE UPTAKE - The subject invention provides materials and methods for modulating cellular glucose uptake. Specifically, in accordance with one embodiment of the subject invention, stem cell factor (SCF) can be used to stimulate cellular glucose uptake. The administration of SCF can also be used to promote Glucose Transporter 4 (GLUT4) expression. In accordance with the subject invention, SCF can be used to improve glucose homeostasis, including in the treatment of diabetes mellitus. | 2015-07-16 |
20150196623 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases - The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. | 2015-07-16 |
20150196624 | HUMAN TISSUE KALLIKREIN 1 GLYCOSYLATION ISOFORMS - Provided are preparations of tissue kallikrein-1 (KLK1) glycoforms having a defined number of oligosaccharide units per KLK1 molecule. Also provided are mixtures of such glycoforms, pharmaceutical compositions containing such glycoforms or mixtures thereof, methods of obtaining the rhKLK1 glycoforms, and therapeutic uses thereof. | 2015-07-16 |
20150196625 | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof - Provided herein are methods of using modified matrix metalloprotease (MMP) enzymes that exhibit regulated activity in the presence of calcium. The methods include conditionally controlling the activity of the MMPs through the use of calcium to treat fibrotic diseases or conditions involving a component of the extracellular matrix (ECM). | 2015-07-16 |
20150196626 | MODULATION OF YEAST-BASED IMMUNOTHERAPY PRODUCTS AND RESPONSES - Disclosed are methods to modulate yeast-based immunotherapy products and the immune responses, prophylactic responses, and/or therapeutic responses elicited by such products. Also disclosed are modified yeast-based immunotherapy products, kits and compositions. | 2015-07-16 |
20150196627 | PLASTID-EXPRESSED MYCOBACTERIUM TUBERCULOSIS VACCINE ANTIGENS ESAT-6 AND MTB72F FUSED TO CHOLERA TOXIN B SUBUNIT - (TB) is caused by | 2015-07-16 |
20150196628 | COMBINATION IMMUNO THERAPY AND RADIOTHERAPY FOR THE TREATMENT OF HER-2-POSITIVE CANCERS - This invention provides methods for inducing an immune response against a Her-2/neu antigen-expressing tumor and for treating the same and vaccinating against the same in human and canine subjects using a combination of radiation therapy and a recombinant attenuated | 2015-07-16 |
20150196629 | Immunogenic Compositions Of Staphylococcus Epidermidis Polypeptide Antigens - The present invention relates to immunogenic compositions, comprising polypeptides isolated from | 2015-07-16 |
20150196630 | RIFT VALLEY FEVER VIRUS REPLICON PARTICLES AND USE THEREOF - Disclosed herein is a robust system for the reverse genetics generation of a Rift Valley fever (RVF) virus replicon particle (VRP | 2015-07-16 |
20150196631 | VACCINE COMPOSITIONS - The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease. | 2015-07-16 |
20150196632 | VACCINE AGAINST RSV - Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype | 2015-07-16 |
20150196633 | HYPO-ALLERGENIC CROSS-LINKED PROTEINS FOR USE IN THE PREVENTION OF AN ALLERGY AGAINST MILK-PROTEINS AND FOR USE IN THE INDUCTION OF ORAL TOLERANCE - The present invention provides a hypo-allergenic cross-linked protein for use in the prevention of an allergy against milk proteins, or for use in the induction of oral tolerance for milk proteins, said cross-linked protein being selected from cross-linked casein, cross-linked caseinate and combinations thereof. The invention further provides a nutritional composition for use in the prevention of an allergy against milk proteins or for use in the induction of oral tolerance against milk proteins. | 2015-07-16 |
20150196634 | CULTURED MYELOID DENDRITIC CELLS ISOLATED FROM PEYERS PATCHES AND USES THEREOF - Cultured lysozyme-secreting myeloid dendritic cells isolated from the subepithelial dome of Peyer's patches in the small intestine are provided. The myeloid dendritic cells are used in screening methods to identify agents which interact with myeloid dendritic cells, for example, antigens, allergens, antimicrobial agents, or agents that modulate the activity of myeloid dendritic cells. The cells are also used to identify agents which bind to and/or are taken up by myeloid dendritic cells, and which can act as delivery vehicles for delivering substances of interest to myeloid dendritic cells in vivo. | 2015-07-16 |
20150196635 | PEPTIDES FOR VACCINE AGAINST BIRCH ALLERGY - The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy. | 2015-07-16 |
20150196636 | IMMUNOREGULATORY VACCINE - An immune-regulatory vaccine comprising—a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix, and—an immunogen with at least one epitope and a second peptidic alpha-helix coiled to the first alpha-helix, a kit for preparing the vaccine, and a sensibilizing vaccine comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a peptidic alpha-helix in a pharmaceutical formulation. | 2015-07-16 |
20150196637 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES - The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided. | 2015-07-16 |
20150196638 | SYSTEM AND METHOD FOR USING ULTRASOUND-STIMULATED MICROBUBBLE EXPOSURES TO INDUCE CERAMIDE ACCUMULATION IN ENDOTHELIAL AND TUMOR CELLS - A system and method for using ultrasound and a microbubble agent to induce ceramide accumulation in a target region including a population of cells associated with a tumor. An ultrasound system is directed to expose a target region in a patient, to which a microbubble agent has been provided, to an ultrasound exposure sufficient to alter gene expressions in cells in the target region so as to induce an accumulation of ceramide in the cells. | 2015-07-16 |
20150196639 | TREATMENT INTERVALS FOR USE OF COMPOSITIONS COMPRISING ENERGY ABSORBING MATERIALS FOR DERMATOLOGICAL APPLICATIONS - The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets. The method of treatment is performed and then, depending upon the desired clinical outcome, repeated after a treatment response interval has elapsed. | 2015-07-16 |
20150196640 | PROGESTERONE FORMULATIONS HAVING A DESIRABLE PK PROFILE - This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount. | 2015-07-16 |
20150196641 | Use of Polymeric Materials with Other Substances for Improved Performance - Methods of enabling or improving the ability of a hydrogel to swell in the stomach of an animal and/or increasing the amount of time said hydrogel remains swollen in the stomach are described herein. In one embodiment, a polymer is administered in combination with one or more pH modifying agents which raise and maintain the pH of the micro environment of the polymer and/or the stomach in order inducing swelling in the polymer. The polymer can be a homopolymer, a copolymer, or a polymer blend or composite. In one embodiment, the polymer is a superabsorbent polymer (“SAP”). The polymers can also be administered with one or more active agents, such as appetite suppressants. The pH modifying agent and/or the active agent can be administered simultaneously with the polymer in the same dosage form, simultaneously with the polymer in separate dosage forms, or sequentially. The compositions are formulated for oral administration. The formulation can include drugs for delivery to the stomach, such as antibiotics, or the hydrogel can be used as a filler, for example, for obesity control. The formulation an also be used to enhance gastric retention, for example, for controlled drug delivery. Methods of delivering a drug are also described herein, along with medicaments for carrying out the methods of the present invention. | 2015-07-16 |
20150196642 | ANTIBODY FORMULATIONS - The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab). | 2015-07-16 |
20150196643 | LIQUID FORMULATION OF LONG-ACTING INSULIN CONJUGATE - The present invention relates to a liquid formulation of long-acting insulin conjugate, comprising a pharmaceutically effective amount of a long-acting insulin conjugate, wherein a physiologically active peptide, which is an insulin, is linked to an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For preventing microbial contamination in multiple uses, a preservative can be added to the formulation. The liquid formulation of the present invention does not comprise a human serum albumin and potentially hazardous factors to body, and thus it has excellent storage stability for insulin conjugate without a risk of viral infection. | 2015-07-16 |
20150196644 | Oral Drug Delivery System - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 2015-07-16 |
20150196645 | Stable Aqueous Formulations of Etanercept - The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same. | 2015-07-16 |
20150196646 | TOPICAL COMPOSITION COMPRISING A FILM-FORMING POLYMER FOR DELIVERING AN ACTIVE INGREDIENT TO SKIN - A film-forming pharmaceutical composition for dermal application comprises at least one therapeutically active ingredient dissolved in a volatile solvent, the composition further comprising a film-forming polymer, a plasticizer and an oily release-enhancing agent. The composition is capable of forming, after application on skin and evaporation of the solvent, a continuous phase comprising the film-forming polymer and the plasticizer and a dispersed phase comprising droplets of the oily release-enhancing agent. | 2015-07-16 |
20150196647 | COMPOSITE ABSORBABLE/BIODEGRADABLE RINGS FOR CONTROLLED DRUG DELIVERY - A fiber-reinforced composite ring for the controlled release of at least one bioactive agent includes a biocompatible matrix reinforced with absorbable/biodegradable fibers capable of providing the mechanical properties needed for inserting and maintaining the ring in a body cavity for a desired period of time. Such ring system as can be used for the intravaginal, intraperitoneal, and subcutaneous delivery of at least one bioactive agent, including those used as contraceptives, antimicrobial agents, and/or antiviral agents, as well as those for the treatment of cancer. | 2015-07-16 |
20150196648 | Methods and Compositions for Treating Prostate Cancer - Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided. | 2015-07-16 |
20150196649 | Compositions and Methods for the Treatment of Intraocular Neovascularization and/or Leakage - The invention provides compositions and methods for the treatment of intraocular neovascularization and/or leakage including wet age-related macular degeneration. The compositions preferably use tyrosine kinase inhibitors with an IC50 for VEGFR2 of 20 nanomolars or less and an IC50 for c-MET of 20 nanomolars or less. | 2015-07-16 |
20150196650 | CARBON NANOTUBE-BASED ANTI-CANCER AGENT CAPABLE OF SUPPRESSING DRUG RESISTANCE - The present invention provides an anticancer agent comprising a multi-walled carbon nanotube and an anticancer drug covalently attached to the surface of the multi-walled carbon nanotube, in order to anticancer agent capable of solving drug resistance problem. | 2015-07-16 |
20150196651 | LIPIDATED PEPTIDES FOR LOWERING BLOOD GLUCOSE - Lipidated analogs of prolactin-releasing peptides (PrRP) and their use in controlling and lowering blood glucose in mammals is disclosed. Useful compounds included lipidated analogs of PrRP20 and PrRP31. Pharmacological effects are demonstrated both in vitro and in vivo. Peripheral administration of the lipidated peptides lowers blood glucose levels. These treatments are applicable for treating impaired glucose tolerance (IGT), and glucose intolerance condition. The disclosed compounds have application in treating medical conditions including diabetes, pre-diabetes, eating disorders, and obesity. | 2015-07-16 |
20150196652 | NUCLEIC ACID COMPLEXES - The present invention relates to complexes of transcription factor decoys, their delivery to bacteria and their formulation. In particular, the present invention resides in an antibacterial complex comprising a nucleic acid sequence and one or more delivery moieties selected from quaternary amine compounds; bis-aminoalkanes and unsaturated derivatives thereof, wherein the amino component of the aminoalkane is an amino group forming part of a heterocyclic ring; and an antibacterial peptide. | 2015-07-16 |
20150196653 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 2015-07-16 |
20150196654 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 2015-07-16 |
20150196655 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION - This disclosure relates to an improved process for the preparation of carbohydrate conjugates. The disclosure also relates to carbohydrate conjugated iRNA agents comprising these carbohydrate conjugates, which have improved purity and are advantageous for the in vivo delivery of the iRNA agents. | 2015-07-16 |
20150196656 | Fusion Proteins Containing Insulin-Like Growth Factor-1 and Epidermal Growth Factor and Variants Thereof and Uses Thereof - Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided. | 2015-07-16 |
20150196657 | Dendritic Polypeptide-Based Nanocarriers for the Delivery of Therapeutic Agents - Dendritic polypeptides useful for the delivery of therapeutic agents into cells are disclosed, together with their methods of preparation. These dendritic polypeptides serve as carriers of drugs, siRNA, aptamers and plasmid DNA in the treatment of various diseases, including cancer. | 2015-07-16 |
20150196658 | Compounds - The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer. | 2015-07-16 |
20150196659 | BIFUNCTIONAL PROTEIN ANCHORS - The disclosure relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allow the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional polypeptide attached to an immunogenic carrier, the bifunctional polypeptide comprising a peptidoglycan binding domain (PBD) through which the polypeptide is attached to the carrier, fused to an antigen binding domain (ABD) to which at least one antigen of interest is bound. Also described is a pharmaceutical (e.g., vaccine) composition comprising an antigen-loaded immunogenic carrier complex. | 2015-07-16 |
20150196660 | ANTI-ETBR ANTIBODIES AND IMMUNOCONJUGATES - The invention provides anti-ETBR antibodies and immunoconjugates and methods of using the same. In some embodiments, an immunoconjugate comprising an antibody that binds ETBR covalently attached to a cytotoxic agent is provided, wherein the antibody binds an epitope within amino acids 64 to 101 of SEQ ID NO: 10. In some embodiments, the cytotoxic agent is a nemorubicin derivative. | 2015-07-16 |
20150196661 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 2015-07-16 |
20150196662 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 2015-07-16 |
20150196663 | Blood-Brain Barrier Targeting Antibodies - A BBB-selective antibody comprising a protein encoded by SEQ ID NO:1 or 3 or comprising a peptide encoded by CDR H1, CDR H2, CDR H3, CDRL1, CDRL2 or CDRL3 of SEQ ID NO:1 or CDR H1, CDR H2, CDR H3, CDRL1, CDRL2, or CDRL3 of SEQ ID NO: 3 is disclosed. | 2015-07-16 |
20150196664 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 2015-07-16 |
20150196665 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 2015-07-16 |
20150196666 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 2015-07-16 |
20150196667 | STERILIZATION OF BIODEGRADABLE HYDROGELS - The present invention relates to a terminal sterilization process for biodegradable PEG-based insoluble hydrogels using irradiation. The presence of a protective solvent ensures that the hydrogel remains intact with functionally preserved three-dimensional and physicochemical properties. | 2015-07-16 |
20150196668 | NANOMEDICINES FOR EARLY NERVE REPAIR - Disclosed are hydrophobically modified nanoparticles and polymeric nanostructures that can be utilized to for the treatment of neuronal injury or neuronal disease in an affected patient, and methods of forming and using the nanoparticles and nanostructures. | 2015-07-16 |
20150196669 | COMPLEX OF GARCINOL, CYCLODEXTRIN AND METHOD THEREOF - The present disclosure discloses a pharmaceutical molecule of Garcinol chemically complexed with cyclodextrins and the use of the complexed molecule in prevention and management of cardiac dysfunction induced by chemotherapy, drugs and/or other insults to the heart caused by lifestyle and disease conditions. The disclosure also relates to a method of extraction and purification of high yield of 95-99% pure Garcinol from | 2015-07-16 |
20150196670 | COMPOSITIONS AND METHODS FOR DUCHENNE MUSCULAR DYSTROPHY GENE THERAPY - The present invention relates to a gene therapy method for the treatment of Duchenne muscular dystrophy, or DMD. | 2015-07-16 |
20150196671 | COMPOSITIONS AND METHODS FOR TREATING DISEASES - The present invention provides compositions and methods of use pertaining to rAAV-mediated delivery of therapeutically effective molecules for treatment of diseases such as Pompe disease. These compositions in combination with various routes and methods of administration result in targeted expression of therapeutic molecules in specific organs, tissues and cells. | 2015-07-16 |
20150196672 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS - The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. | 2015-07-16 |
20150196673 | ANTICANCER THERAPY - A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions. | 2015-07-16 |
20150196674 | Dynamic Enhanced and Diffuse Broad Spectrum UVC or Alternative Controlled Ionizing Radiation Source Emitters for Mobile and Fixed Placement Disinfection of Clinical Surfaces - A system providing effective, broad spectrum UV-C or other ionizing radiation clinical surface disinfection, high intensity UV-C light emitting diodes (LEDs) of incrementally differing wavelengths are sequentially embedded in densely packed reflective nacels (cups or pockets) forming the surface of a rotating spherical or hemispherical structure. A combination of UV-C emitter component location and activation with the rotational and reciprocal elevation functions of such structures produces complete and continuous environmental overlapping UV-C energy scattering. | 2015-07-16 |
20150196675 | Purified Hydrogen Peroxide Gas Microbial Control Methods and Devices - The present invention relates to methods and devices for providing microbial control and/or disinfection/remediation of an environment. The methods generally comprise: generating a Purified Hydrogen Peroxide Gas (PHPG) that is substantially free of, e.g., hydration, ozone, plasma species, and/or organic species; and directing the gas comprising primarily PHPG into the environment such that the PHPG acts to provide microbial control and/or disinfection/remediation in the environment, preferably both on surfaces and in the air. | 2015-07-16 |
20150196676 | SYSTEM FOR REMOTELY CONTROLLING AND MANAGING STERILIZER - Disclosed herein is a system for remotely controlling and managing a sterilizer. The system for remotely controlling and managing a sterilizer according to an embodiment of the present invention includes N sterilizers configured to sterilize sterilization targets, a mobile terminal configured to receive a control command for each sterilizer or display information related to the sterilizer, and an integrated sterilizer management server connected to the N sterilizers over a network, and configured to transmit the control command received from the mobile terminal to the corresponding sterilizer, allow the corresponding sterilizer to be driven in compliance with the control command, collect current status information of the N sterilizers, and transmit the collected current status information to the mobile terminal. | 2015-07-16 |
20150196677 | Air Freshener Composition and Methods Thereof - Disclosed in certain embodiments is an air freshener composition comprising a matrix comprising a fragrance dispersed in a thermo-reversible cross-linked polymer, the matrix having a melting point of at least 120° F. | 2015-07-16 |
20150196678 | Combination Air Freshener, Odor Absorber and Moisture Absorber - A multiple purpose container for an air freshener, odor absorber and moisture absorber in a single product includes a tub with a lid that has openings, a basket suspended in the tub that has a vertical partition for holding an air freshener on one side and a moisture absorber on the other side, the basket includes openings on one side of the vertical partition that holds the moisture absorber to allow liquid absorbed to drain from the basket to the space below the basket. | 2015-07-16 |
20150196679 | HEMOSTATIC DEVICE - A hemostatic device, method of making, and method of using for internal and external applications to wounds in the body of a patient to induce hemostasis at an anatomical site. | 2015-07-16 |
20150196680 | GELATIN SPONGE COMPRISING AN ACTIVE INGREDIENT, ITS PREPARATION AND USE - The present invention is directed to a method for manufacturing a cross-linked gelatin sponge having a surface by providing a cross-linked gelatin sponge, wetting the surface of the sponge by applying a sufficient amount of liquid comprising a protein or peptide active ingredient, wherein a sufficient amount of liquid is one that retains the flexibility of the sponge even after drying. The sponge is then dried the sponge to obtain a flexible, dry and ready to use cross linked gelatin sponge having a layer of protein or peptide active ingredient on the surface thereof | 2015-07-16 |
20150196681 | CYANOACRYLATE TISSUE ADHESIVES WITH DESIRABLE PERMEABILITY AND TENSILE STRENGTH - A sterilized cyanoacrylate adhesive composition including a cyanoacrylate composition and a cure speed enhancer, wherein said sterilized cyanoacrylate adhesive composition does not cure upon sterilization, and wherein the composition when cured to form a film on a patient's tissue has water vapor transmission rate from about 950 to about 3000 g/m | 2015-07-16 |
20150196682 | Lung Volume Reduction Therapy Using Crosslinked Biopolymers - One aspect of the present invention relates to bronchoscopic lung volume reduction using solutions of biopolymers that can be polymerized in situ with a crosslinker and a polymeric additive which accelerates the cross-linking reaction. In certain embodiments, the biopolymer solutions can be in the form of a foam or gel. The biopolymer compositions disclosed herein may also be used for indications other than lung volume reduction, such as sealing fistulas or performing emergency tamponade of vessels. | 2015-07-16 |
20150196683 | GELATIN-TRANSGLUTAMINASE HEMOSTATIC DRESSINGS AND SEALANTS - An adhesive material for medical use comprising gelatin and a non-toxic cross-linking material such as transglutaminase. An optional embodiment of the invention includes dressings in which a layer of a transglutaminase is sandwiched between a first and second layer of gelatin. The hemostatic products are useful for the treatment of wounded tissue. | 2015-07-16 |
20150196684 | POLYSACCHARIDE AND PROTEIN-POLYSACCHARIDE CROSS-LINKED HYDROGELS FOR SOFT TISSUE AUGMENTATION - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 2015-07-16 |
20150196685 | FUNCTIONALIZED SUBSTRATES AND METHODS OF MAKING SAME - Polymer substrates including adhesion layers for activating the surface of the substrate are provided, thereby allowing the substrate to react with organic, inorganic, metallic and/or organometallic materials. The surface of the polymer substrate is coated with a metal oxide layer that is subjected to conditions adequate to form an oxide adhesion layer. Combining deposition techniques for formation of functionalized polymer surfaces with photolithographic techniques enables spatial control of RGD presentation at the polymer surfaces are achieved with sub-cellular resolution. Surface patterning enables control of cell adhesion location at the surface of the polymer and influences cell shape. Metallization of polymers as described herein provides a means to prepare metal-based electrical circuitry on a variety of flexible substrates. | 2015-07-16 |
20150196686 | DRIED AND IRRADIATED SKIN EQUIVALENTS FOR READY USE - The present invention relates generally to systems and methods for preparing, storing, shipping and using skin equivalents made by organotypic culture. In particular, the present invention relates to systems and methods for producing, transporting, storing and using skin equivalents produced by organotypic culture at reduced temperatures, preferably from 2-8 degrees Celsius to ambient temperature. The methods include sterile packaging of the grafts so that the sterility and integrity of the package is maintained until the time of use for grafting purposes. | 2015-07-16 |
20150196687 | Compositions and Uses to Govern Cancer Cell Growth - The invention relates to composition and a method of using the composition for modulting proliferation, invasiveness, the expression of a biomarker of an abnormal cell, of reducing the risk of patient cell becoming abnormal, or of modulating proliferation of a carcinoma-associated fibroblast or of a tumor-associated macrophage. The invention also relates to a method of culturing the composition to produce molecules that modulate abnormal cell proliferation, invasiveness, or metastasis. The composition comprises a biocompatible matrix and cells engrafted thereon. | 2015-07-16 |
20150196688 | Glycosaminoglycan and Synthetic Polymer Material for Blood-Contacting Applications - Provided herein is a composite, comprising: a polymer host selected from the group consisting of low-density polyethylene (LDPE), linear low-density polyethylene (LLDPE), polyethylene terephthalate (PET), polytetrafluoroethylene (PTFE), and polypropylene (PP), polyurethane, polycaprolactone (PCL), polydimethylsiloxane (PDMS), polymethylmethacrylate (PMMA), and polyoxymethylene (POM); and a guest molecule comprising hyaluronic acid; wherein the guest molecule is disposed within the polymer host, and wherein the guest molecule is covalently bonded to at least one other guest molecule. Also provided herein are methods for forming the composite, and blood-contracting devices made from the composite, such as heart valves and vascular grafts. | 2015-07-16 |
20150196689 | MULTIPHASIC BONE GRAFT SUBSTITUTE MATERIAL - The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, comprising i) a calcium sulfate hemihydrate powder, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 50 weight percent based on the total weight of the particulate composition; ii) a monocalcium phosphate monohydrate powder; iii) a non-porous β-tricalcium phosphate powder; and iv) a porous β-tricalcium phosphate powder. Bone graft substitute cements made therefrom, a bone graft substitute kit comprising the particulate composition, methods of making and using the particulate composition, and articles made from the bone graft substitute cement are also provided. | 2015-07-16 |
20150196690 | COATINGS WITH TUNABLE MOLECULAR ARCHITECTURE FOR DRUG-COATED BALLOON - A drug delivery balloon is provided, the a balloon having an outer surface, and a tunable coating disposed on at least a length of the balloon surface. The tunable coating includes a first therapeutic agent and a first excipient, wherein the cytostatic therapeutic agent and the at least one excipient have a weight ratio of about 20:1 to about 1:20, and further wherein the coating provides increased efficiency of therapeutic transfer to a body lumen. | 2015-07-16 |
20150196691 | COATED STENT - A coating ( | 2015-07-16 |
20150196692 | MULTIPLE DRUG DELIVERY FROM A BALLOON AND A PROSTHESIS - System for treating vascular disease comprising a balloon having an outer surface for temporary contact with a vessel wall when in an expanded state, a coating disposed on at least a portion of the outer surface, the coating including an initial amount of a cytostatic agent selected from the group consisting of Zotarolimus (ABT578), everolimus, pimecrolimus, and a combination thereof, the coating being capable of maintaining a therapeutically effective amount of the cytostatic agent on the outer surface for delivery to a vessel wall, and further wherein between about 4.9% to about 23% of the initial amount of the cytostatic agent on the outer surface remains disposed on the outer surface after delivery of the therapeutically effective amount of the cytostatic agent to the vessel wall, and optionally, a stent disposed on the balloon. | 2015-07-16 |
20150196693 | PASSIVATED METALLIC IMPLANTABLE MEDICAL DEVICES INCLUDING RADIOPAQUE MARKERS - The present disclosure is directed to methods of manufacturing and passivating stents and other implantable medical devices including one or more attached radiopaque markers. In one embodiment, the method includes providing a metallic implantable medical device body without any radiopaque marker(s) attached thereto, primary electropolishing the device body without any markers attached thereto, attaching one or more radiopaque markers to the device body, and lightly electropolishing the device including device body and attached radiopaque markers. Light electropolishing removes no more than about 5 percent by weight of the device (i.e., the device body and attached marker(s)). Light electropolishing passivates the exposed surfaces of the device body and markers, while also providing electropolishing to the region of any welds where the radiopaque marker(s) attach to the device body. | 2015-07-16 |
20150196694 | Directional Bandage for Delivering Oxygenated Solution to Wound and Method of Treating a Wound Using Same - Dispersing a gas into solution for intentionally directional inflow and outflow through a bandage to a human tissue wound for treatment of said wound with the gas-containing solution. Methods of using the solution to treat a wound are provided. The gas molecules may be mostly oxygen and/or contain supplemental additions of carbon dioxide, nitrous or nitric oxide. | 2015-07-16 |
20150196695 | WOUND TREATMENT DEVICE - A method of wound treatment can comprise providing a wound treatment device with a wound surface cover and a wound insert. The method can also include positioning the wound insert in contact with the wound, covering the wound insert and wound with the wound surface cover, affixing the wound surface cover to the skin surrounding the wound and compressing the wound insert by applying pressure to the wound surface cover. | 2015-07-16 |
20150196696 | DEVICE AND METHOD FOR COLLECTING AND DISPENSING COLOSTRUM - A device for collecting colostrum from a breast of a human and dispensing the colostrum to a newborn may include a colostrum collection member and a plunger. The colostrum collection member may include a funnel-shaped proximal portion with a wide, open end for facilitating collection of expressed colostrum, a narrow distal portion with a small-diameter opening for dispensing the expressed colostrum to the newborn, and a cylindrical barrel portion between the funnel-shaped proximal portion and the narrow distal portion. The plunger is configured for advancement through the wide, open end and the barrel portion of the collection member to force the colostrum out of the small-diameter opening. | 2015-07-16 |
20150196697 | Biphasic and Dynamic Adjustable Support Devices and Methods with Assist and Recoil Capabilities for Treatment of Cardiac Pathologies - The present invention provides a biphasic and dynamic direct cardiac contact device adapted to be implanted in a patient suffering from congestive heart failure and related cardiac pathologies, said cardiac device having means for providing ventricular assist, ventricular support and diastolic recoil, or for providing ventricular support and diastolic recoil only. | 2015-07-16 |